Genomic characterization of breast cancer cells resistant to the histone deacetylase inhibitor romidepsin

被引：0
|
作者：
Ali-Rahmani, Fatima G. [1 ]
Robey, Robert [1 ]
Lack, Justin [1 ]
Tebase, Bethelihem [1 ]
Bates, Susan [2 ]
Gottesman, Michael [1 ]
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] Columbia Univ, Ithaca, NY USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-LB-241
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-241
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Romidepsin: a novel histone deacetylase inhibitor for cancer
    Bertino, Erin M.
    Otterson, Gregory A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (08) : 1151 - 1158
  • [2] Clinical development of histone deacetylase inhibitor romidepsin
    Guan, Peng
    Fang, Hao
    DRUG DISCOVERIES AND THERAPEUTICS, 2010, 4 (06): : 388 - 391
  • [3] Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies
    Jain, Nitin
    Odenike, Olatoyosi
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (18) : 3073 - 3084
  • [4] The histone deacetylase inhibitor romidepsin is a potential therapeutic for metastatic osteosarcoma
    Seiden, Emily E.
    Richardson, Spencer M.
    Ramnath, Shrey
    Whiteside, Tia
    Coy, Kathryn L.
    Sinn, Anthony L.
    Capitano, Maegan L.
    Pollok, Karen E.
    Collier, Chris D.
    Greenfield, Ed M.
    CANCER RESEARCH, 2024, 84 (06)
  • [5] The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
    Conforti, Franco
    Davies, Elizabeth R.
    Calderwood, Claire J.
    Thatcher, Thomas H.
    Jones, Mark G.
    Smart, David E.
    Mahajan, Sumeet
    Alzetani, Aiman
    Havelock, Tom
    Maher, Toby M.
    Molyneaux, Philip L.
    Thorley, Andrew J.
    Tetley, Teresa D.
    Warner, Jane A.
    Packham, Graham
    Ganesan, A.
    Skipp, Paul J.
    Marshall, Benjamin J.
    Richeldi, Luca
    Sime, Patricia J.
    O'Reilly, Katherine M. A.
    Davies, Donna E.
    ONCOTARGET, 2017, 8 (30) : 48737 - 48754
  • [6] Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
    Pojani, Eftiola
    Barlocco, Daniela
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (07) : 1290 - 1303
  • [7] Metabolic reprogramming in KRAS mutant cancer cells may cause sensitivity to the histone deacetylase (HDAC) inhibitor romidepsin
    Basseville, Agnes
    Sourbier, Carole
    Robey, Robert W.
    Sackett, Dan L.
    Linehan, W. Marston
    Bates, Susan E.
    CANCER RESEARCH, 2015, 75
  • [8] Synergistic Prostate Cancer Targeted Radiosensitization by Gold Nanoparticles and Histone Deacetylase Inhibitor Romidepsin
    Hara, D.
    Ma, W.
    Tao, W.
    Dogan, N.
    Pollack, A.
    Ford, J.
    Shi, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E521 - E522
  • [9] The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells
    Rhodes, Lyndsay V.
    Nitschke, Ashley M.
    Segar, H. Chris
    Martin, Elizabeth C.
    Driver, Jennifer L.
    Elliott, Steven
    Nam, Seung Yoon
    Li, Meng
    Nephew, Kenneth P.
    Burow, Matthew E.
    Collins-Burow, Bridgette M.
    ONCOLOGY REPORTS, 2012, 27 (01) : 10 - 16
  • [10] Use of class I histone deacetylase inhibitor romidepsin in combination regimens
    Petrich, Adam
    Nabhan, Chadi
    LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1755 - 1765
12345